Home › NCT04993859

Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children

Who can join

Ages 5 to 13 · All sexes

Inclusion Criteria:

* Children aged 5-13 years old
* A history of cancer
* Treatment with a chemotherapy regimen including VCR and/or DOX
* Completion of chemotherapy at least one year prior to study enrollment and survey completion.

Exclusion Criteria:

* Patients with a:
* Primary pelvic tumor
* Pelvic irradiation
* Pre-existing bladder/bowel dysfunction
* Spinal defects
* Neurologic disorder
* Neuro-oncologic tumor or brain metastasis
* Cyclophosphamide or ifosfamide therapy

About the study

The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.

What is being tested

• Non-invasive Urodynamic Test (niUDS) (diagnostic test)
• Urinary proteomic screen (diagnostic test)
• Dysfunctional Voiding Symptom Score Survey (DVSS) (other)

Sponsor: University of Colorado, Denver · Participants: 152 · Started: Jun 2, 2021

Contact the study team

• Gemma Beltran · Phone: (720) 777-4418

Official record on ClinicalTrials.gov — NCT04993859

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.